Cumulative incidence and risk factors of mitoxantrone-induced cardiotoxicity in children: a systematic review
- 31 March 2004
- journal article
- research article
- Published by Elsevier BV in European Journal of Cancer
- Vol. 40 (5), 643-652
- https://doi.org/10.1016/j.ejca.2003.12.006
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic reviewAnnals of Oncology, 2002
- Cohort studies: marching towards outcomesThe Lancet, 2002
- Verbesserung der Prognose bei Kindern mit AML: Ergebnisse der Studie AML-BFM 931Klinische Padiatrie, 2001
- Treatment‐related deaths during induction and first remission of acute myeloid leukaemia in children treated on the Tenth Medical Research Council Acute Myeloid Leukaemia Trial (MRC AML10)British Journal of Haematology, 1999
- Users' Guides to the Medical LiteratureJAMA, 1994
- Cytosine arabinoside and mitoxantrone treatment of relapsed or refractory childhood leukemia: Initial response and relationship to multidrug resistance gene 1Medical and Pediatric Oncology, 1994
- Hochdosiertes ARA-C in Kombination mit Mitoxantron bei der Therapie der AML im KindesalterOncology Research and Treatment, 1987
- Mitoxantrone: A New Anticancer Drug with Significant Clinical ActivityAnnals of Internal Medicine, 1986
- Novantrone for childhood malignant solid tumorsInvestigational New Drugs, 1986
- Mitoxantrone in the treatment of relapsed and refractory acute leukemiaInvestigational New Drugs, 1985